Non-CF bronchiectasis of adults: short review for clinical practice
Position paper of Board of disease with bronchial obstruction Czech Pulmonological and Phthiseological Society Czech Medical Association of J. E. Purkyne

Authors: Zuzana Antušová 1,2;  Libor Fila 3;  Vladimír Herout 4;  Eva Kočová 5;  Kateřina Neumannová 6;  Jaromír Zatloukal 7;  Vladimír Koblížek 2
Authors‘ workplace: Plicní ambulance, GEPAMED – NEXTCLINIC, Hradec Králové 1;  Plicní klinika LF UK a FN Hradec Králové 2;  Pneumologická klinika 2. LF UK a FN v Motole, Praha 3;  Klinika nemocí plicních a tuberkulózy LF MU a FN Brno, pracoviště Bohunice 4;  Radiologická klinika LF UK a FN Hradec Králové 5;  Katedra fyzioterapie Fakulty tělesné kultury UP v Olomouci 6;  Klinika plicních nemocí a tuberkulózy LF UP a FN Olomouc 7
Published in: Vnitř Lék 2017; 63(11): 821-833
Category: Reviews


Bronchiectasis is a clinically important, but poorly understood, pulmonary condition characterized by dilated and thick-walled bronchi. Bronchiectasis remains a significant cause of morbidity and mortality around the world. Targeted effort to early high-resolution computed tomography diagnosis and detailed confirmation of causation are in the spotlight of respiratory physicians in the developed countries. The risk population consists of subjects with persistent and/or productive cough, where another clear diagnosis has not been performed. Specific treatment tailored on underlying diseases and non-specific airway clearance techniques are able to improve symptoms, and reduce lung impairment. Evidence-based treatment algorithms for anti-inflammatory, and antibiotic treatment of stable non-CF BE will have to await large-scale, long-term controlled studies. Surgery should be reserved for individuals with highly symptomatic, localized bronchiectasis who have failed medical management. Unfortunately, there have been few well designed longitudinal or cross-sectional studies in the field of bronchiectasis. To give truly meaningful and generalizable results, a longitudinal observational study of bronchiectasis would require to enrol several thousand patients, more than any one center can enrol. The European Bronchiectasis Registry will create an open, pan-European registry of patients with non-CF bronchiectasis. The authors emphatically recommend that all respiratory specialist managed non-CF BE subjects should be actively involved in the European Bronchiectasis Registry.

Key words:
bronchiectasis – diagnosis – registry – treatment


1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65(7): 577. Dostupné z DOI: <>.

2. Weycker D, Edelsberg J, Oster G et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med 2005; 12(4): 205–209.

3. EMBARC – The European Bronchiectasis Registry. Dostupné z WWW: <>.

4. Chalmers JD, Goeminne P, Aliberti S et al. The Bronchiectasis Severity Index An International Derivation and validation Study. Am J Respir Crit Care Med 2014; 189(5): 576–585. Dostupné z DOI: <–1575OC>.

5. Martinez-Garcia MA, de Gracia J, Vendrell Relat M et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014; 43(5): 1357–1367. Dostupné z DOI: <>.

6. Saleh AD, Hurst JR. How to assess the severity of bronchiectasis. Eur Respir J 2014; 43(5): 1217–1219. Dostupné z DOI: <>.

7. Haworth CS, Foweraker JE, Wilkinson P et al. Inhaled Colistin in Patients with Bronchiectasis and Chronic Pseudomonas aeruginosa Infection. Am J Respir Crit Care Med 2014; 189(8): 975–982. Dostupné z DOI: <–2208OC>.

8. Doporučení české vakcinologické společnosti pro pneumokokovou vakcinaci v dospělosti [online] aktualizováno 16.dubna 2013. Dostupné z WWW: <>.

9. Floto RA, Haworth CS. Bronchiectasis. European Respiratory Monograph; 52. European Respiratory Society Journals: 2010. ISBN 978–1849840118.

10. Alteburg J, Wortel K, de Graaff CS et al. Validation of visual analogue score (LRTI-VAS) in non-CF bronchiectatis. Clin Respir J 2016; 10(2): 168–175. Dostupné z DOI: <>.

11. Zemánková J, Stříž I. Imunomodulační účinky makrolidových antibiotic. Alergie 2012; 14(4): 271–281.

12. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007; 132(5): 1565–1572.

13. Loebinger MR, Wells AU, Hansell DM et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009; 34(4): 843–849. Dostupné z DOI: <>.

14. Murray MP, Govan JRW, Docherty CJ et al. A randomised controlled trial of nebulised gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183(4): 491–499. Dostupné z DOI: <–0756OC>.

15. Barker AF, Couch L, Fiel SB et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 481–485.

16. Spruit, MA, Singh SJ, Garvey C et al. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188(8): e13-e64. Dostupné z DOI: <–1634ST>. Erratum in Am J Respir Crit Care Med. 2014; 189(12): 1570.

17. Bolton CE, Blakey JD, Morgan MD. British Thoracic Society guidelines on pulmonary rehabilitation in adults: your opinion is noted. Thorax 2014; 69(4): 388–389. Dostupné z DOI: <–204754>.

18. Smolíková L, Máček M. Respirační fyzioterapie a plicní rehabilitace. Národní centrum ošetřovatelství a nelékařských zdravotnických oborů: Brno 2010. ISBN 978–80–7013–527–3.

19. Neumannová K, Zatloukal J, Koblížek V et al. Doporučený postup pro plicní rehabilitaci. 2014. Dostupné z WWW: <>.

20. Kim SJ, Im JG, Kim IO et al. Normal bronchial and pulmonary arterial diameters measured by thin section CT. J Comput Assist Tomogr 1995; 19(3): 365–369.

21. Hansell DM, Bankier AA, MacMahon H et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246(3): 697–722. Dostupné z DOI: <>.

22. Tsang KW, Tan KC, Ho PL et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60(3): 239–243.

23. Martinez-Garcia MA, Perpina-Tordera M, Roman-Sanchez P et al. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med 2006; 100(9): 1623–1632.

24. Kapur N, Bell S, Kolbe J et al. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev 2009; (1): CD000996. Dostupné z DOI: <>.

25. Henkle E, Aksamit TR, Barker AF et al. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis: Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017. pii: S0012–3692(17)30810–3. Dostupné z DOI: <>.

26. Fjaellegaard K, Sin MD, Browatzki A et al. Antibiotic therapy for stable non-CF bronchiectasis in adults – A systematic review. Chron Respir Dis 2017; 14(2): 174–186. Dostupné z DOI: <>.

27. Hurst JR, Elborn JS, De Soyza A. [BRONCH-UK Consortium]. COPD – bronchiectasis overlap syndrome. Eur Respir J 2015; 45(2): 310–313. Dostupné z DOI: <>.

28. Panda A, Bhalla AS, Goyal A. Bronchial artery embolization in hemoptysis: a systematic review. Diagn Interv Radiol 2017; 23(4): 307–317. Dostupné z DOI: <>.

Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue 11

2017 Issue 11

Most read in this issue

This topic is also in:

Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account